Financial Data and Key Metrics Changes - The company reported a 27% increase in revenue to $14.5 million for Q4 2025, with full-year revenue also growing 27% to $52.2 million compared to 2024 [4][18] - Gross profit for Q4 was $11.1 million, up from $8.5 million in the prior year, increasing gross margin to 76% [19] - Net income for Q4 was $2.9 million, compared to $1.5 million in the same period of 2024, with full-year net income of approximately $7.6 million compared to $2.9 million in 2024 [23] Business Line Data and Key Metrics Changes - A total of 95 Deep TMS systems were shipped during Q4, bringing the installed base to approximately 1,700 systems, a 26% increase year-over-year [4][18] - The book-to-bill ratio improved to 1.4x from 1.2x in the previous quarter, indicating strong demand [5] Market Data and Key Metrics Changes - Remaining performance obligations reached $70 million, representing a 43% growth from $49 million a year ago, reflecting strong demand and long-term commitments [5][24] - The company estimates it has penetrated less than 10% of the market for Deep TMS, indicating significant growth potential [7] Company Strategy and Development Direction - The company is focusing on expanding reimbursement coverage with payers across the U.S. to increase market share [8] - A strategic initiative is in place to secure minority equity investments in high-performing mental health providers, which is expected to facilitate faster access to interventional psychiatry modalities [14][15] - The company aims to develop a portfolio of data-driven technology-enabled neuromodulation solutions to serve more patients and settings [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum in the business and expects revenue in the range of $66 million to $68 million for 2026, representing a year-over-year growth rate of 27%-30% [24][25] - The company anticipates adjusted EBITDA of $12 million to $14 million for 2026, indicating expected growth of 86%-100% over 2025 [25] Other Important Information - The FDA granted label expansion for the Deep TMS system to treat adolescents aged 15 to 21 suffering from major depressive disorder, expanding the addressable patient population [9] - The company received a $2.5 million NIH grant for a study on Deep TMS for alcohol use disorder, highlighting ongoing clinical research efforts [12][13] Q&A Session Summary Question: Can you give us a better sense of the Q4 placements as far as units sold, units leased, and also any color regarding OCD placements? - Management reported that 95 systems were shipped during Q4, with more than 50% including H7 coils [26] Question: Can you talk about the Deep TMS 360 trial? - The trial is designed for addiction and neurology markets, with 10 centers actively recruiting patients for alcohol use disorder and three centers for Alzheimer's disease [28][29] Question: Was there any pricing change in 2025 or anticipated for 2026? - Management does not anticipate a decrease in average selling price and aims to optimize pricing based on the value provided [31]

Smith Douglas Homes (NYSE:SDHC) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Company ParticipantsGreg Bennett - President, Chairman, and CEOJoe Thomas - SVP of Accounting and FinanceMike Dahl - Managing DirectorRuss Devendorf - EVP and CFOConference Call ParticipantsNikhil Kalra - AnalystRafe Jadrosich - Senior AnalystRyan Gilbert - Managing Director and Housing and Real Estate Services AnalystOperatorGood morning. I would like to welcome everyone to the Smith Douglas Homes fourth quarter and full year ...

Financial Data and Key Metrics Changes - Consolidated fourth quarter 2025 revenue was $154.8 million, down from $163.3 million in the prior year, primarily due to softening customer demand [7] - Adjusted EBITDA for the fourth quarter was $2.3 million, compared to $0.9 million in the prior year, with adjusted EBITDA margins increasing to 1.5% from 0.6% [7][8] - Full year consolidated revenue was $649 million, down from $723.4 million in the prior year, with adjusted EBITDA at $17.8 million, down from $23.2 million [9][10] - Free cash flow for the full year was $33.7 million, up $21.5 million from last year, enabling a reduction in net debt by over $35 million [5][11] Business Line Data and Key Metrics Changes - Global Seating segment revenues decreased by 5.6% to $70.7 million in the fourth quarter, but adjusted operating income increased to $1.8 million [12] - Global Electrical Systems segment revenues increased by 12.7% to $49.7 million in the fourth quarter, with adjusted operating income rising to $0.9 million [13][14] - Trim Systems and Components revenues decreased by 22.5% to $34.4 million in the fourth quarter, resulting in an adjusted operating loss of $1.4 million [16][17] Market Data and Key Metrics Changes - The North American Class 8 truck market is experiencing a challenging demand environment, with a forecasted 4% increase in year-over-year volumes for 2026 [18] - The construction market is expected to grow in the low single-digit percentage range, driven by lower interest rates and fiscal stimulus initiatives [18] Company Strategy and Development Direction - The company is focusing on operational efficiency improvements and has announced a new contract with Zoox for autonomous vehicle components, indicating a strategic shift towards electric and autonomous vehicle markets [19][20] - The company aims to grow its Global Electrical Systems segment by more than 10% in 2026, supported by new business wins and increased capacity utilization [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about end market recovery and expects improved financial performance in 2026, with guidance for net sales between $660 million and $700 million [21][22] - The company anticipates generating positive free cash flow in 2026, which will be used to continue paying down debt and improving net leverage [21][22] Other Important Information - The company achieved a net leverage ratio of 4.1 times at the end of 2025, down from 4.7 times at the end of 2024 [10] - Interest expense for the fourth quarter was $4.2 million, up from $2.2 million in the prior year, driven by higher interest rates [8] Q&A Session Summary Question: Can you provide more color on the two key programs that started ramping in the third quarter? - Management confirmed that both programs are progressing as planned, with the Zoox program on track for volume production by the latter part of the second quarter [26][27] Question: What is the outlook for the aftermarket business? - The aftermarket business is expected to grow, driven by improved operational efficiencies and promotional initiatives [32][36] Question: What are the assumptions behind the guidance range for Adjusted EBITDA? - The guidance range reflects current macroeconomic trends and the anticipated recovery in Class 8 truck production, with expectations for significant drop-through of incremental top line [81][82]

Financial Data and Key Metrics Changes - Total revenues for 2025 were $180.5 million, representing a 12% year-over-year increase from $161 million in 2024 [5][17] - Adjusted EBITDA was $42 million, up 23% year-over-year from $34.1 million in 2024 [5][19] - Net income for 2025 was $20.2 million or $0.35 per diluted share, a 40% increase compared to $14.5 million or $0.25 per diluted share in 2024 [19] - Cash and cash equivalents at year-end 2025 were $75.5 million, down from $78.4 million in December 2024 [19] Business Line Data and Key Metrics Changes - Sales of KedRAB increased to approximately $54 million in 2025, exceeding the contract minimum commitment [10] - GLASSIA contributed total revenue of $35 million, with growth in both ex-U.S. markets and royalty income from Takeda [10] - Revenues from Cytogam declined due to increased usage of antivirals, with ongoing efforts to demonstrate its advantages through a new clinical study [11][12] Market Data and Key Metrics Changes - The company secured a $10 million-$14 million extension of an existing tender from Canadian Blood Services for various products, ensuring ongoing sales in Canada from Q2 2026 to Q1 2028 [17] - The company anticipates growth in its distribution segment through the launch of additional biosimilars in Israeli markets and expansion into the MENA region [9][14] Company Strategy and Development Direction - The company focuses on expanding its commercial product portfolio, including investment in FDA-approved specialty plasma-derived products and biosimilars [9] - Plans to ramp up plasma collection at new centers in Houston and San Antonio, with expected annual revenues of $8 million-$10 million per center at full capacity [15] - The company is pursuing new business development and M&A opportunities to enhance its product portfolio and generate synergies [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational and financial performance, despite geopolitical challenges in the Middle East [4] - The company affirmed its 2026 annual guidance of $200 million-$205 million in revenues and $50 million-$53 million in adjusted EBITDA, representing growth from 2025 results [8] - Management emphasized the importance of Cytogam in organ transplant protection and the potential for increased usage following clinical studies [25] Other Important Information - A dividend of $0.25 per share was declared, totaling approximately $14.4 million, reinforcing confidence in business prospects [6][7] - The company plans to continue investing in growth while maintaining dividend payments [26] Q&A Session Summary Question: CMV market and Cytogam usage - Management noted no changes in CMV management protocols but acknowledged increased access to antivirals affecting Cytogam usage [23][24] Question: M&A opportunities and dividend implications - Management confirmed that the dividend payment does not indicate a change in M&A opportunities, expressing optimism for securing transactions in 2026 [26] Question: Plasma collection growth margin benefits - Management expects growth margin benefits from plasma collection to start impacting gross profit in 2027 and beyond [27] Question: Plasma collection center ramp-up - Current ramp-up is at 30%-40%, with full capacity expected by the end of 2027 [31] Question: Timing for new biosimilars launch - New biosimilars are expected to launch around mid-2026, with sales ramping up based on market demand [32] Question: Dividend payment timing - The entire dividend will be paid in the second quarter [39]

Sprinklr (NYSE:CXM) Q4 2026 Earnings call March 11, 2026 08:30 AM ET Speaker7Greetings. Welcome to Sprinklr's fourth quarter fiscal year 2026 earnings call. At this time, all participants will be in listen-only mode. The question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero from your telephone keypad. Please note this conference is being recorded. At this time, I'll turn the conference over to Eric Sgro, He ...

Financial Data and Key Metrics Changes - In Q4 2025, the company delivered 780 homes, generating $260 million in revenue, a 9% decrease from the previous year [10] - Home closing gross margin was 19.9%, down from 25.5% in Q4 2024 [10] - Net income for Q4 was $17 million, or $0.39 per diluted share, compared to $30 million in the prior year [11] - For the full year 2025, the company delivered 2,908 homes, a 1% increase over 2024, with revenue of $971 million, essentially flat year-over-year [12] - Adjusted net income for Q4 was $12.8 million, down from $22.7 million in the same period last year [12] Business Line Data and Key Metrics Changes - The company generated 532 net new orders in Q4, reflecting a challenging sales environment [5] - Average sales price for homes was $334,000, down from $340,000 in 2024 [12] - SG&A expense for Q4 was $36 million, approximately 13.8% of revenue, compared to 14.9% in Q4 2024 [11] Market Data and Key Metrics Changes - The company ended the year with 512 homes in backlog, with an average sales price of $337,000, representing a backlog value of approximately $173 million [15] - Total controlled lots increased by 14% to approximately 22,300 lots, primarily through option contracts [16] Company Strategy and Development Direction - The company aims to grow volume and gain market share through targeted investments and a disciplined approach to home building [7] - The focus remains on building affordable homes in markets with strong population growth and job creation [8] - The company maintains a conservative balance sheet and prioritizes operational discipline to position itself for long-term success [9] Management's Comments on Operating Environment and Future Outlook - Management noted that the housing market has been in a recessionary environment for about 18 months, driven by affordability pressures and higher mortgage rates [19] - The macroeconomic environment remains uncertain, with mixed signals from recent economic data [20] - The company is optimistic about the spring selling season but acknowledges that demand remains inconsistent [6] Other Important Information - The company plans to repurchase shares when market conditions allow, while continuing to prioritize investments in land and community growth [20] - For Q1 2026, the company expects closings between 575 and 625 homes, with average sales prices between $330,000 and $335,000 [21] Q&A Session Summary Question: Can you provide insights on sales pace, pricing, and incentives trends in Q1? - Management indicated that sales pace followed traditional seasonal patterns, with an uptick in February and early March [24][26] Question: Are there any trends in strengths and weaknesses across major markets? - Management noted similarities in market pacing and expressed hope for new markets once models are open [28] Question: What is driving the decision to lean back into incentives? - Management explained that they are monitoring traffic and sales on a community basis, aiming to balance pace and margin [34] Question: How does the spec count look heading into Q1 2026? - Management stated that specs are running about half of current inventory, with a focus on pre-sold homes to maximize value [64] Question: What is the strategy around land purchases? - The company prefers finished lot takedowns and is seeing softening opportunities in better locations [68]

BrainsWay (NasdaqGM:BWAY) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Speaker5Good day, and welcome to the BrainsWay fourth quarter and full year 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad, and to withdraw your questi ...

Commercial Vehicle Group (NasdaqGS:CVGI) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Speaker6Good morning, ladies and gentlemen, and welcome to CVG's fourth quarter 2025 earnings conference call. During today's presentation, all parties will be in a listen only mode. Following the presentation, the conference will be opened for questions with instructions to follow at that time. As a reminder, this conference call is being recorded. I would now like to turn the call over to Michelle Harves, Vice Presid ...

Verrica Pharmaceuticals (NasdaqGM:VRCA) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Speaker8Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals fourth quarter and year-end 2025 corporate update conference call. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may b ...

Kamada (NasdaqGS:KMDA) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Speaker5Greetings, and welcome to the Kamada Ltd. fourth quarter 2025 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the call, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to Brian Ritchie, Managing Dir ...